Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer

Gynecologic Oncology

Volumn 139, Issue 2, 2015, Pages 228-235

  Eng, Kevin H ^a   Hanlon, Bret M ^b   Bradley, William H ^c   Szender, J Brian ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b University of Wisconsin   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chemotherapy; Ovarian cancer; Survival analysis; Treatment free interval

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; TAXOID;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; FEMALE; HUMAN; ONCOLOGICAL PARAMETERS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT FREE INTERVAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; AGE; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL ANALYSIS; TIME FACTOR; TUMOR RECURRENCE;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYTOREDUCTION SURGICAL PROCEDURES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS; TOPOTECAN;

EID: 84952630402     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.09.011     Document Type: Article

References (19)

1. S. Bhoola, and W.J. Hoskins Diagnosis and management of epithelial ovarian cancer Obstet. Gynecol. 107 6 2006 1399 1410
2. R.J. Morgan, R.D. Alvarez, D.K. Armstrong, and et al. Ovarian cancer, version 3.2012 J. Natl. Compr. Cancer Netw. 10 2012 1339 1349
3. K. Ushijima Treatment for recurrent ovarian cancer at first relapse J. Oncol. 2010 2010 497-429
4. S. Vaughan, J. Coward, R. Bast, and et al. Rethinking ovarian cancer: recommendations for improving outcomes Nat. Rev. Cancer 11 2011 719 725
5. J.A. Ledermann, and R.S. Kristeleit Optimal treatment for relapsing ovarian cancer Ann. Oncol. 21 S7 2010 vii218 vii222
6. D.K. Armstrong Relapsed ovarian cancer: challenges and management for a chronic disease Oncologist 7 2002 20 28
7. T.J. Herzog Recurrent ovarian cancer: how important is it to treat disease progrsesion? Clin. Cancer Res. 10 2004 7439 7449
8. M. Markman, R. Rothman, T. Hakes, and et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J. Clin. Oncol. 9 1991 389 393
9. M. Markman, and W. Hoskins Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J. Clin. Oncol. 10 1992 520 528
10. C.H. Bailey, G. Jameson, C. Sima, and et al. Progression-free survival decreases with each subsequent therapy in patients presenting for phase I clinical trials J. Cancer 3 2012 7 13
11. S. Cooke, and J. Brenton Evolution of platinum resistance in high-grade serous ovarian cancer Lancet Oncol. 12 2011 1169 1174
12. M.A. Bookman Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy Oncologist 4 1999 87 94
13. S.M. Campos, and S. Ghosh A current review of targeted therapeutics for ovarian cancer J. Oncol. 149 2010 362
14. M.L. Kurta, R.P. Edwards, K.B. Moysich, and et al. Prognosis and conditional disease-free survival among patients with ovarian cancer 22 36 2014 4102 4112
15. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
16. G.J. Rustin, I. Vergote, E. Eisenhauer, and et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA125 agreed by the Gynecological Cancer Intergroup Int. J. Gynecol. Cancer 21 2 2011 419 423
17. R Core Team R: A Language and Evironment for Statistical Computing. Vienna, Austria 2014
18. D.W. Hosmer, S. Lemeshow, and S. May Applied Survival Analysis 2nd ed. 2008 Wiley
19. K. Hess, and R. Gentleman muhaz: hazard function estimation in survival analysis 2014 (http://CRAN.R-project.org/package=muhaz)